Co-founder and the Chief Medical Officer of Assembly Pharma (2012) and CMO/VP R&D for Assembly Biosciences (f\k\a Ventrus Bioscience), which reverse merged with Assembly Pharma in 2014. He helped ASMB raise > $300M to move 2 generations of novel HBV meds into Ph 1 and Ph 2 clinical studies. Uri has held roles at Schering Plough, Roche, and Gilead Science, and received medical training at UMDNJ, NYU and the NIH. Uri was a visiting partner at YC before he started Pardes to cure COVID-19

Uri Lopatin

Pardes Biosciences